clinical trial · NCT05845645
A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
UCB Biopharma SRL·phase1·completed·n = 73
Healthy Study ParticipantsUCB0599EsomeprazolePlacebo
brief summary
The purpose of the study is to estimate the relative bioavailability of 2 new UCB0599 formulations under elevated and normal gastric pH conditions in healthy participants (Part A) and to asess the safety, tolerability and pharmacokinetics of UCB0599 in healthy participants of Japanese and Chinese origins (Part B).
started
May 31, 2023
primary completion
Apr 13, 2024
completion
Apr 13, 2024
last updated
Dec 22, 2025
official title
A 2-Part Study to Evaluate the Relative Bioavailability of 2 New Formulations of UCB0599 and the Effect of Esomeprazole on the PK of UCB0599 in Healthy Participants (Part A, Open-Label) and to Assess the Safety/Tolerability and PK of UCB0599 in Healthy Participants of Japanese and Chinese Origins (Part B, Double-Blind)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol